Journal · Updated 2026-08-11

The GLP-1 Insurance Doors: Every FDA-Approved Indication That Opens Coverage in 2026

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

Why doors beat drugs

The whole apparatus of coverage — formularies, prior authorization, appeals — keys on the indication written into the PA request. A plan that flatly excludes Zepbound "for weight loss" may cover the identical pen for documented sleep apnea; a Medicaid program that removed Wegovy's obesity coverage still processes it for cardiovascular risk reduction. This is not a loophole and must not be treated as one: the door has to be a diagnosis you actually have, documented in your chart by your clinician — presenting a diagnosis you don't have to obtain coverage is insurance fraud, full stop. The honest version of the strategy is simpler and more common than the dishonest one: many people carrying excess weight also carry one of the other five diagnoses undiagnosed or under-documented, and asking the clinician "do any of the covered indications apply to me, on the evidence?" is legitimate medicine that changes the coverage answer.

Door one: type 2 diabetes — the wide door

Ozempic, Mounjaro, and Rybelsus carry the type 2 diabetes indication, and every state Medicaid program and essentially every commercial formulary covers the class for it, prior authorization attached. The PA package is the class's most standardized: the diagnosis with A1c documentation, and usually metformin step-therapy — either current use or a documented reason it failed or can't be used. Our diabetes-context guide covers the Mounjaro-versus-Zepbound framing, and the PA guide carries the general checklist. This door's constraint is definitional: it exists only for diagnosed type 2 diabetes — prediabetes does not open it, a line plans police closely.

Door two: chronic weight management — the door that varies

Wegovy and Zepbound carry the weight-management indication (label criteria: BMI of thirty or more, or twenty-seven-plus with a weight-related condition), and this is the door whose existence varies by payer more than any other. Commercial plans split — many cover with PA, many employers carve the category out entirely; the insurance-first guide walks the benefits check that answers it in one call. Medicaid covers it only where a state has affirmatively opted in — thirteen states at KFF's January 2026 count and roughly eleven by mid-2026 tracker counts, a churning list our 2026 change ledger tracks with dates. Medicare historically excluded it, with 2026's demonstration cracking that door open — below. When this door is closed, the remaining four are the ones to read carefully, because they were built for exactly the population standing at this one.

Door three: cardiovascular risk reduction — the everywhere door

Wegovy's SELECT-trial indication — reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity — is the strategically remarkable one: it is an FDA-approved, non-weight-loss indication, which places it inside the coverage Medicaid programs must generally provide and outside the weight-loss exclusion states use. Prior authorization still applies everywhere, and "established cardiovascular disease" means documented events or disease — a prior heart attack or stroke, or diagnosed peripheral arterial disease — not risk factors alone. The documentation is the history itself plus the BMI criterion. For the large population with a cardiac history who were told "your plan doesn't cover weight-loss drugs," this door is frequently the accurate second question, and our SELECT deep-dive reads the underlying evidence.

Door four: obstructive sleep apnea — the newest tirzepatide door

Zepbound's December 2024 indication for moderate-to-severe OSA with obesity made tirzepatide the first medication approved for sleep apnea, and it opens payer categories that weight management alone does not. The PA package centers on the sleep study: a documented AHI in the moderate-to-severe range, the obesity criterion, and — plan depending — the relationship to CPAP therapy (some ask about concurrent use or intolerance). The sleep-apnea article covers the AHI evidence and the practical framing. For the many undiagnosed apneics in the eligible-weight population, a sleep study is both good medicine and, incidentally, door-opening documentation — in that order.

Doors five and six: kidneys and liver

Chronic kidney disease: Ozempic's January 2025 indication — reducing kidney-disease progression and cardiovascular death in adults with type 2 diabetes and CKD, on the FLOW trial — is a diabetes-plus door: it requires the T2D diagnosis, then adds the kidney documentation (eGFR and albuminuria staging). Where it applies, it converts a routine diabetes PA into a strongly supported one. MASH: Wegovy's 2025 accelerated approval for metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis created the newest non-weight door — one trackers note sits outside state weight-loss exclusions the same way the cardiovascular door does. The diagnosis rests on liver findings (imaging or biopsy-supported fibrosis staging), making this the most documentation-heavy door on the list; our liver-disease guide maps the territory. Both doors reward the same move: bringing your full chart, not just your weight history, to the coverage conversation.

The government-payer overlay, dated

Two federal timelines reshape the doors this year and next, per KFF's January 2026 analysis. Medicare: a short-term demonstration allows Part D enrollees access to obesity medications beginning July 2026 — the fifty-dollar pathway our Medicare guide details — with the CMS Innovation Center's five-year BALANCE model, announced December 2025, implementing in Part D in January 2027. Medicare has also long covered the non-weight indications on their own terms. Medicaid: the weight door is the state option tracked in our Medicaid hub and dated state records (California, North Carolina); the other five doors run on the federal medically-accepted-indication rules everywhere, PA attached. The order of operations this page implies is the one the appeal guide completes: doors first, PA built to the door's criteria, appeal on denial — and only then the cash math, which exists for the doors' genuine leftovers.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.